Debiopharm
 | |
| File:Logo debio color tag.jpg | |
| Company type | Société Anonyme |
|---|---|
| Industry | biopharmaceutical |
| Founded | Lausanne, Switzerland (1979) |
| Founder | Dr Rolland-Yves Mauvernay |
| Headquarters | Lausanne, Switzerland |
Area served | Worldwide |
Key people |
|
| Products | |
| Owner | family-owned |
Number of employees | 350 |
| Website | www.debiopharm.com |
Debiopharm Group (Debiopharm) is a family-owned biopharmaceutical group of companies headquartered in Lausanne, Switzerland. It was founded in 1979 by Rolland-Yves Mauvernay.[1]
The group works through its subsidiaries:[2]
- Debiopharm International SA, which in-licenses product candidates or technologies, develops them, and then licenses them to third parties for commercialization;[3]
- Debiopharm Research and Manufacturing SA, which provides contract manufacturing and contract research services to Debiopharm;[4]
- Debiopharm Investment SA, which manages the group's money and invests in real estate and in other companies; and[5]
- Debiopharm Diagnostics SA, which invests in diagnostics companies.[6]
As of 2010 two drugs had reached the market through its efforts: oxaliplatin for the treatment of cancer, and depot formulations of triptorelin, a gonadotropin-releasing hormone agonist that is approved to treat advanced prostate cancer.[7]
References
- ^ Bloomberg profile: Debiopharm Group. Page accessed May 12, 2016
- ^ Frost & Sullivan Nov 25 2010 Movers & Shakers Interview with Maurice Wagner, Debiopharm Group
- ^ Bloomberg profile: Debiopharm International. Page accessed May 12, 2016
- ^ Bernard Tappy for In Vivo Magazine. 2013 Debiopharm Research and Manufacturing SA.
- ^ Swiss Private Equity & Corporate Finance Association Debiopharm Investment SA Page accessed May 12, 2016
- ^ Bloomberg profile: Debiopharm Diagnostics. Page accessed May 12, 2016
- ^ "Triptorelin". drugs.com. Retrieved 11 November 2016.
